NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Abeona Therapeutics Inc. ABEO
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$5.8M
EPS · FY25
$1.01
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
70.0%
Net margin · FY25
1223.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 5.8M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
1223 cents of every revenue dollar became profit this year.
Per share
USD 1.01
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
70.0%
Return on equity, FY2025
ROE
Operating margin-1536.9%
Net margin1223.1%
Return on assets43.3%
Each USD of equity produced 70 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−10.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+60.3%
−10.3%
+18.8%
+18.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 219.6M
total assets, end of FY2025
Total assetsUSD 219.6M
EquityUSD 159.2M
CashUSD 78.4M
Gross debtUSD 20.0M
Net debtUSD -58.4M
Current ratio6.93×
The company holds more cash than debt.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
·
0.0
0.0
0.0
0.0
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.1
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
·
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.1
−0.1
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
EPS, diluted $
1.01
−1.55
−2.53
−5.53
−0.86
−0.91
−1.51
−1.19
−0.66
−0.64
−0.53
−15.26
3.04
−0.52
−0.22
−0.60
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
70.0
−216.6
−260.6
−114.8
−117.2
−60.0
−48.8
−37.3
−20.3
−26.2
−40.1
·
·
·
·
·
Shares out B
0.06
0.05
0.03
0.02
0.01
0.10
0.08
0.05
0.05
0.04
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 47
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed